Cocrystal Pharma (NASDAQ: COCP) investors reelect full board and ratify 2026 auditor
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Cocrystal Pharma, Inc. held its 2026 Annual Meeting of Stockholders on July 14, 2026. Stockholders voted on electing five directors, ratifying the independent auditor for the fiscal year ending December 31, 2026, and a possible adjournment to solicit additional proxies if needed.
All five director nominees were elected, with votes for each ranging from 5,914,522 to 6,293,331, and 2,860,552 broker non-votes recorded for each nominee. Stockholders ratified Weinberg & Company as the independent registered public accounting firm, with 9,181,034 votes for, 174,923 against, and 10,587 abstentions. Because Proposals 1 and 2 received sufficient support, the adjournment proposal was moot.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for top director nominee: 6,293,331 votes
Lowest votes for director nominee: 5,914,522 votes
Broker non-votes per director: 2,860,552 shares
+3 more
6 metrics
Votes for top director nominee
6,293,331 votes
Votes for Fred Hassan in Proposal 1 director elections at 2026 Annual Meeting
Lowest votes for director nominee
5,914,522 votes
Votes for Steven Rubin in Proposal 1 director elections at 2026 Annual Meeting
Broker non-votes per director
2,860,552 shares
Broker non-votes recorded for each director nominee in Proposal 1
Votes for auditor ratification
9,181,034 votes
Votes for Proposal 2 to ratify Weinberg & Company for fiscal year ending December 31, 2026
Votes against auditor ratification
174,923 votes
Votes against Proposal 2 ratifying Weinberg & Company as independent registered public accounting firm
Abstentions on auditor ratification
10,587 votes
Abstentions on Proposal 2 at the 2026 Annual Meeting
Key Terms
broker non-votes, independent registered public accounting firm, definitive proxy statement, adjournment
4 terms
broker non-votes regulatory
"Broker Non-Votes 2,860,552"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm regulatory
"appointment of Weinberg & Company as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
definitive proxy statement regulatory
"all as described in more detail in the Company’s definitive proxy statement filed"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
adjournment regulatory
"approval of an adjournment of the 2026 Annual Meeting to a later date or time"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Cocrystal Pharma (COCP) stockholders vote on at the 2026 Annual Meeting?
Stockholders voted on electing five directors, ratifying Weinberg & Company as independent auditor for 2026, and a potential adjournment proposal. These items were described in the definitive proxy statement filed May 27, 2026, and the meeting was held on July 14, 2026.
Were all director nominees elected at Cocrystal Pharma (COCP)’s 2026 Annual Meeting?
Yes, all five director nominees were elected to serve until the next annual meeting and until successors are qualified. Votes for individual nominees ranged from 5,914,522 to 6,293,331, with 2,860,552 broker non-votes recorded for each nominee and varying abstentions.
How did Cocrystal Pharma (COCP) stockholders vote on ratifying Weinberg & Company as auditor?
Stockholders strongly supported ratification of Weinberg & Company as independent registered public accounting firm for 2026, with 9,181,034 votes for, 174,923 against, and 10,587 abstentions. This approval confirms the company’s choice of auditor for the year ending December 31, 2026.
What are broker non-votes reported in Cocrystal Pharma (COCP)’s 2026 director elections?
For each director nominee, there were 2,860,552 broker non-votes. Broker non-votes occur when brokers hold shares for clients but are not instructed how to vote on non-routine matters, so those shares are not counted as for or against the proposals.
What happened to the adjournment proposal at Cocrystal Pharma (COCP)’s 2026 Annual Meeting?
The adjournment proposal was rendered moot because Proposals 1 and 2 received sufficient votes for approval. The adjournment item would have allowed postponing the meeting to solicit additional proxies if support for key proposals had been insufficient.
Who is serving as Cocrystal Pharma (COCP)’s independent registered public accounting firm for 2026?
Weinberg & Company will serve as independent registered public accounting firm for the fiscal year ending December 31, 2026. Stockholders ratified this appointment with 9,181,034 votes for, 174,923 against, and 10,587 abstentions at the 2026 Annual Meeting.